Skip to content

Contact +44 (0) 20 7060 7474 email us

Drug Delivery

Drug Delivery Technologies

Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies

Publication Date September 2008
Publisher Arrowhead
Product Type Report
Pages 283
ISBN Number not applicable
Product Code ARR00028

Price

£2,310.00
approximately: $3,498 | €2,578

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

The drug delivery industry has in recent years become a key partner for pharmaceutical companies in their efforts to maximize the patent lives of successful products. Drug delivery companies not only stand to benefit from patent expiry by providing their reformulation services to pharmaceutical companies, but also by producing their own versions of branded products with improved delivery mechanisms. Thus, post-patent expiry sales can be switched from the ethical manufacturer to the drug delivery sector.

Drug Delivery Technologies: Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies is an up-to-date guide that assesses the current state of the drug delivery industry and its application to both the pharmaceutical and biotech industries. While the sector is still dominated by oral technologies, drug delivery systems have expanded to include more novel devices such as needleless injectables, PEGylation platforms and microelectromechanical devices. These technological advances extend the duration of a drugs action, increase delivery to target sites, reduce delivery to unwanted sites, and maximize drug absorption.

The expanding market for biotechnology and gene-based products, which by their very nature are difficult to administer, represents an emerging opportunity for drug delivery technologies. These technologies are first expected to come to market as reformulations of existing macromolecular therapies, such as insulin. This report analyzes the markets for oral, inhalable, injectable, transmucosal, transdermal and niche drug delivery technologies as they apply to both biotech and traditional pharmacological compounds.

Key Features of This Report

  • A thorough overview of both marketed and emerging drug delivery technologies set to impact the global pharmaceutical market
  • Analysis of the opportunities and threats to the global drug delivery industry
  • Profiles of drug delivery companies along with key financial figures and technology/product portfolios
  • Market analysis and outlook for the leading drug delivery technologies, including oral, injectable, inhalable, transdermal, transmucosal and niche technologies
  • Profiles of key emerging drug delivery technologies and profiles of leading companies, by type of technology
  • An overview of the global drug delivery market, with sales for key drug delivery categories and key products within each one of the them
  • Identification of key areas associated with the successful development of new drug delivery systems
  • Critical assessment of market trends, forecasts and problems in the global drug delivery market
  • Explanations of key technologies and mechanism of action of new drug delivery technologies and products utilizing them
  • Thorough descriptions of important areas of research and development in the drug delivery market

What questions does this report answer?

  • What are the key trends in the field of drug delivery as a whole?
  • What are the major issues involved in the research and development of more effective drug delivery systems?
  • What types of drug delivery technologies are currently in research and development in each of the main drug delivery categories?
  • What is the value of new drug delivery technologies in terms of a products lifecycle management?
  • Which new drug delivery systems are likely to provide the best commercial opportunities for their manufacturers?

Highlights of this report

  • Discussion and analysis of the problems associated with the use of traditional drug delivery technologies: lack of patient compliance, considerable adverse effects, inferior clinical efficacy due to the lack of targeted delivery
  • Identification of the hallenges to the development of better, more efficacious drug delivery technologies, with fewer side effects
  • Focused analysis of the global market for major drug delivery technologies: oral, inhalable, injectable, transdermal, transmucosal and topical, as well as niche technologies, such as gene delivery
  • Identification of the major products in research and development utilizing new technologies
  • Highlights of the drug delivery systems that are most likely to impact the global market

Reasons to purchase

  • Provides a comprehensive description of the current state of affairs in the global drug delivery field
  • Provides a comprehensive description of the main drug delivery technologies and key products within each of the categories
  • Asesses key products and technologies in clinical development
  • Provides a guide to optimizing drug reformulation processes
  • Provides a guide to business models of drug delivery companies
  • Identifies key issues facing drug delivery and pharmaceutical companies in the development of new drug delivery systems

Contents

  • 1 Introducing The Field Of Drug Delivery
    • 1.1 The Value Of Drug Delivery Systems
    • 1.2 Drug Delivery And Product Differentiation
    • 1.3 Drug Delivery And Patent Extension
    • 1.4 The Optimal Time For Reformulation
    • 1.5 Optimizing R&d Returns Through Drug Delivery
    • 1.6 Opportunities And Threats To The Drug Delivery Sector
      • 1.6.1 Opportunities For Growth In The Drug Delivery Sector
      • 1.6.2 Threats To Additional Growth In The Drug Delivery Sector
    • 1.7 Business Models Of Drug Delivery Companies
  • 2 An Overview Of Drug Delivery Technologies
    • 2.1 Oral Drug Delivery
      • 2.1.1 Controlled Release
      • 2.1.2 Sustained Release
      • 2.1.3 Chronomodulation
      • 2.1.4 Rapid Dissolving And Taste-Masking Tablets
      • 2.1.5 Macromolecular Drug Delivery
      • 2.1.6 Microemulsion
      • 2.1.7 Pulsatile Drug Delivery
    • 2.2 Inhalable Drug Delivery
      • 2.2.1 Nebulizers
      • 2.2.2 Metered Dose Inhalers (Mdis)
      • 2.2.3 Dry Powder Inhalers (Dpis)
      • 2.2.4 Limitations Of Pulmonary Delivery Systems For Systemic Delivery
      • 2.2.5 Aqueous Systems
      • 2.2.6 Crystallization Technology
      • 2.2.7 Electrohydrodynamic (Ehd) Aerosol Delivery
      • 2.2.8 Liposomal Systems
    • 2.3 Injectable Drug Delivery
      • 2.3.1 Sustained Release Injectable Systems
      • 2.3.2 Liposomal Systems
      • 2.3.3 Needleless Systems
      • 2.3.4 New Injectable Technologies
    • 2.4 Transmucosal Drug Delivery
      • 2.4.1 Buccal Delivery
      • 2.4.2 Nasal
      • 2.4.3 Rectal
      • 2.4.4 Vaginal
    • 2.5 Transdermal Drug Delivery
      • 2.5.1 Passive Formulations
      • 2.5.2 Active Formulations
    • 2.6 Niche Technologies
      • 2.6.1 Topical Systems
      • 2.6.2 Gene Delivery
      • 2.6.3 Implantable Systems
      • 2.6.4 Drug Delivery Microchips
      • 2.6.5 Nanotechnology
  • 3 Overview Of Global Drug Delivery Market
    • 3.1 Importance Of Drug Delivery
    • 3.2 Global Drug Delivery Market By Geographic Area
    • 3.3 Global Drug Delivery Market By Segment
    • 3.4 Global Drug Delivery Market Forecasts
  • 4 Drug Delivery Market Analysis
    • 4.1 Key Market Segments
      • 4.1.1 Oral Drug Delivery
        • 4.1.1.1 Sales Of Products Utilizing Oral Drug Delivery Technology
        • 4.1.1.2 Key Therapeutic Areas For Oral Drug Delivery
        • 4.1.1.3 Key Oral Drug Delivery Products Impacting Global Market
        • 4.1.1.4 The Outlook For Oral Drug Delivery Technology
        • 4.1.1.5 Drivers And Restraints
      • 4.1.2 Inhalable Drug Delivery
        • 4.1.2.1 Sales Of Products Utilizing Inhalable Drug Delivery Technology
        • 4.1.2.2 Key Therapeutic Areas For Inhalable Drug Delivery
        • 4.1.2.3 Key Inhalable Drug Delivery Products Impacting Global Market
        • 4.1.2.4 The Outlook For Inhalable Drug Delivery Technology
        • 4.1.2.5 Drivers And Restraints
      • 4.1.3 Injectable Drug Delivery
        • 4.1.3.1 Sales Of Products Utilizing Injectable Drug Delivery Technology
        • 4.1.3.2 Key Therapeutic Areas For Injectable Drug Delivery
        • 4.1.3.3 Key Injectable Drug Delivery Products Impacting Global Market
        • 4.1.3.4 The Outlook For Injectable Drug Delivery Technology
        • 4.1.3.5 Drivers And Restraints
      • 4.1.4 Transmucosal Drug Delivery
        • 4.1.4.1 Sales Of Products Utilizing Transmucosal Drug Delivery Technology
        • 4.1.4.2 Key Therapeutic Areas For Transmucosal Delivery
        • 4.1.4.3 Key Transmucosal Drug Delivery Products Impacting Global Market
        • 4.1.4.4 The Outlook For Transmucosal Drug Delivery Technology
        • 4.1.4.5 Drivers And Restraints
      • 4.1.5 Transdermal Drug Delivery
        • 4.1.5.1 Sales Of Products Utilizing Transdermal Drug Delivery Technology
        • 4.1.5.2 Key Therapeutic Areas For Transdermal Drug Delivery
        • 4.1.5.3 Key Transdermal Drug Delivery Products Impacting Global Market
        • 4.1.5.4 The Outlook For Transdermal Drug Delivery Technology
        • 4.1.5.5 Drivers And Restraints
      • 4.1.6 Niche Drug Delivery Technologies
        • 4.1.6.1 Sales Of Products Utilizing Niche Drug Delivery Technologies
        • 4.1.6.2 Key Niche Drug Delivery Technology Product Impacting Global Market
        • 4.1.6.3 The Outlook For Niche Drug Delivery Technologies
        • 4.1.6.4 Drivers And Restraints
  • 5 Emerging Drug Delivery Technologies: Oral Drug Delivery
    • 5.1 Key Product Profiles
    • 5.2 Key Company Involvement In The Field Of Oral Drug Delivery
      • 5.2.1 Alza
      • 5.2.2 Biovail
      • 5.2.3 Cardinal Health
      • 5.2.4 Depomed
      • 5.2.5 Emisphere
      • 5.2.6 Ethypharm
      • 5.2.7 Penwest
  • 6 Emerging Drug Delivery Technologies: Inhalable Drug Delivery
    • 6.1 Key Product Profiles
    • 6.2 Key Company Involvement In The Field Of Inhalable Drug Delivery
      • 6.2.1 3m
      • 6.2.2 Alkermes
      • 6.2.3 Aradigm
      • 6.2.4 Nektar
      • 6.2.5 Skyepharma
  • 7 Emerging Drug Delivery Technologies: Injectable Drug Delivery
    • 7.1 Key Product Profiles
    • 7.2 Key Company Involvement In The Field Of Injectable Drug Delivery
      • 7.2.1 Alkermes
      • 7.2.2 Alza
      • 7.2.3 Enzon
      • 7.2.4 Ethypharm
      • 7.2.5 Macromed
      • 7.2.6 Nektar
      • 7.2.7 Qlt
  • 8 Emerging Drug Delivery Technologies: Transmucosal Drug Delivery
    • 8.1 Key Product Profiles
    • 8.2 Key Company Involvement In The Field Of Transmucosal Drug Delivery
      • 8.2.1 Generex
      • 8.2.2 Nastech
      • 8.2.3 Pherin
  • 9 Emerging Drug Delivery Technologies: Transdermal Drug Delivery
    • 9.1 Key Product Profiles
    • 9.2 Key Company Involvement In The Field Of Transdermal Drug Delivery
      • 9.2.1 3m
      • 9.2.2 Altea Therapeutics
      • 9.2.3 Alza
      • 9.2.4 Aradigm
      • 9.2.5 Noven
  • 10 Emerging Drug Delivery Technologies: Niche Drug Delivery Technologies
    • 10.1 Key Product Profiles
    • 10.2 Key Company Involvement In Niche Drug Delivery Technologies
      • 10.2.1 Alza
      • 10.2.2 Connetics (Now Stiefel Laboratories)
      • 10.2.3 Inovio
      • 10.2.4 Macrochem
      • 10.2.5 Nexmed
      • 10.2.6 Psivida
      • 10.2.7 Qlt
      • 10.2.8 Skyepharma
  • 11 Key Drug Delivery Company Profiles
    • 11.1 3m Pharmaceuticals
    • 11.2 Alkermes
    • 11.3 Altea Therapeutics
    • 11.4 Alza (Johnson & Johnson)
    • 11.5 Aradigm
    • 11.6 Bioject
    • 11.7 Biovail
    • 11.8 Cardinal Health
    • 11.9 Cima Labs (Cephalon)
    • 11.10 Connetics (Stiefel Laboratories Inc.)
    • 11.11 Cydex Pharmaceuticals
    • 11.12 Delsite Biotechnologies (Carrington Laboratories)
    • 11.13 Depomed
    • 11.14 Dor Biopharma
    • 11.15 Durect
    • 11.16 Emisphere
    • 11.17 Enzon
    • 11.18 Ethypharm
    • 11.19 Eurand
    • 11.20 Generex
    • 11.21 Inovio (Formerly Genetronics)
    • 11.22 Ivax (Part Of Teva)
    • 11.23 Macrochem
    • 11.24 Macromed (Now Protherics)
    • 11.25 Nastech (Now Mdrna)
    • 11.26 Nektar
    • 11.27 Nexmed
    • 11.28 Noven
    • 11.29 Psivida
    • 11.30 Penwest
    • 11.31 Pherin Pharmaceuticals
    • 11.32 Qlt
    • 11.33 Skyepharma
    • 11.34 Watson Pharmaceuticals
    • 11.35 Zogenix
    • Tables
    • Table 2.1 Drugs Suitable Or Unsuitable For Controlled Release
    • Table 2.2 Advantages And Disadvantages Of Transdermal Delivery
    • Table 3.1 Global Sales Of Drug Delivery Systems By Key Segments, 2007
    • Table 3.2 Forecast Global Sales Of Drug Delivery Systems By Segment, Us$ Billion
    • Table 4.1 Key Oral Drug Delivery Products, 2004-2007** ($ Mn)
    • Table 4.2 Leading Oral Drug Delivery Companies 2007, Key Products And Sales 2007 ($Mn)
    • Table 4.3 Key Inhalable Drug Delivery Products, 2004-2007** ($ Mn)
    • Table 4.4 Key Injectable Drug Delivery Products, 2004-2007** ($ Mn)
    • Table 4.5 Leading Injectable Drug Delivery Companies 2007, Key Products And Sales 2007 ($ Mn)
    • Table 4.6 Key Transmucosal Drug Delivery Products, 2004-2007**
      • ($ Mn)
    • Table 4.7 Key Transdermal Drug Delivery Products, 2004-2007#
      • ($ Mn)
    • Table 4.8 Key Topical Drug Delivery Products, 2007
    • Table 4.9 Key Niche Drug Delivery Products, 2004-2007 ($ Mn)
    • Table 5.1 Key Oral Drug Delivery R&d Pipeline Drugs, 2008
    • Table 6.1 Key Inhalable Drug Delivery R&d Pipeline Drugs, 2008
    • Table 7.1 Key Injectable Drug Delivery R&d Pipeline Drugs, 2008
    • Table 8.1 Key Transmucosal Drug Delivery R&d Pipeline Drugs, 2008
    • Table 9.1 Key Transdermal Drug Delivery R&d Pipeline Drugs, 2008
    • Table 10.1 Key Topical Drug Delivery R&d Pipeline Drugs, 2008
    • Table 10.2 Key Niche Drug Delivery R&d Pipeline Drugs, 2008
    • Table 11.1 3m Key Financials, 2003-2007 (Us$Mn)
    • Table 11.2 3m Drug Delivery Portfolio, 2008
    • Table 11.3 Alkermes Key Financials, 2003-2007 (Us$Mn)
    • Table 11.4 Alkermes Drug Delivery Portfolio, 2008
    • Table 11.5 Altea Therapeutics Drug Delivery Portfolio, 2008
    • Table 11.6 Alza Drug Delivery Portfolio, 2008
    • Table 11.7 Aradigm Key Financials, 2003-2007 (Us$Mn)
    • Table 11.8 Aradigm Drug Delivery Portfolio, 2008
    • Table 11.9 Bioject Key Financials, 2003-2007 (Us$Mn)
    • Table 11.10 Bioject Drug Delivery Portfolio, 2008
    • Table 11.11 Biovail Key Financials, 2003-2007 (Us$Mn)
    • Table 11.12 Biovail Drug Delivery Portfolio, 2008
    • Table 11.13 Cardinal Health Key Financials, 2003-2007 (Us$Mn)
    • Table 11.14 Cardinal Health Drug Delivery Portfolio, 2008
    • Table 11.15 Cephalon Key Financials, 2003-2007 (Us$Mn)
    • Table 11.16 Cima Labs Drug Delivery Portfolio, 2008
    • Table 11.17 Connetics Key Financials, 2003-2007 (Us$Mn)
    • Table 11.18 Connetics Drug Delivery Portfolio, 2008
    • Table 11.19 Cydex Drug Delivery Pipeline, 2008
    • Table 11.20 Carrington Laboratories Key Financials, 2003-2007 (Us$Mn)
    • Table 11.21 Depomed Key Financials, 2003-2007 (Us$Mn)
    • Table 11.22 Depomed Drug Delivery Portfolio, 2008
    • Table 11.23 Dor Biopharma Key Financials, 2003-2007 (Us$Mn)
    • Table 11.24 Dor Biopharma Drug Delivery Portfolio, 2008
    • Table 11.25 Durect Key Financials, 2003-2007 (Us$Mn)
    • Table 11.26 Durect Drug Delivery Portfolio, 2008
    • Table 11.27 Emisphere Key Financials, 2003-2007 (Us$Mn)
    • Table 11.28 Emisphere Drug Delivery Portfolio, 2008
    • Table 11.29 Enzon Key Financials, 2003-2007 (Us$Mn)
    • Table 11.30 Enzon Drug Delivery Portfolio, 2008
    • Table 11.31 Ethypharm Drug Delivery Portfolio, 2008
    • Table 11.32 Eurand Key Financials, 2003-2007 (Us$Mn)
    • Table 11.33 Eurand Drug Delivery Portfolio, 2008
    • Table 11.34 Generex Key Financials, 2003-2007 (Us$Mn)
    • Table 11.35 Generex Drug Delivery Portfolio, 2008
    • Table 11.36 Inovio Key Financials, 2003-2007 (Us$Mn)
    • Table 11.37 Inovio Drug Delivery Portfolio, 2008
    • Table 11.38 Ivax Key Financials, 2003-2007 (Us$Mn)
    • Table 11.39 Ivax Drug Delivery Portfolio, 2008
    • Table 11.40 Macrochem Key Financials, 2003-2007 (Us$Mn)
    • Table 11.41 Macrochem Drug Delivery Portfolio, 2008
    • Table 11.42 Macromed Drug Delivery Portfolio, 2008
    • Table 11.43 Nastech Key Financials, 2003-2007 (Us$Mn)
    • Table 11.44 Nastech Drug Delivery Portfolio, 2008
    • Table 11.45 Nektar Key Financials, 2003-2007 (Us$Mn)
    • Table 11.46 Nektar Drug Delivery Portfolio, 2008
    • Table 11.47 Nexmed Key Financials, 2003-2007 (Us$Mn)
    • Table 11.48 Nexmed Drug Delivery Portfolio, 2008
    • Table 11.49 Noven Key Financials, 2003-2007 (Us$Mn)
    • Table 11.50 Noven Drug Delivery Portfolio, 2008
    • Table 11.51 Psivida Key Financials, 2003-2007 (Us$Mn)
    • Table 11.52 Psivida Drug Delivery Portfolio, 2008
    • Table 11.53 Penwest Key Financials, 2003-2007 (Us$Mn)
    • Table 11.54 Penwest Drug Delivery Portfolio, 2008
    • Table 11.55 Pherin Pharmaceuticals Drug Delivery Portfolio, 2008
    • Table 11.56 Qlt Key Financials, 2003-2007 (Us$Mn)
    • Table 11.57 Qlt Drug Delivery Portfolio, 2008
    • Table 11.58 Skye Pharma Key Financials, 2003-2007 (Us$Mn)
    • Table 11.59 Skyepharma Drug Delivery Portfolio, 2008
    • Table 11.60 Watson Key Financials, 2003-2007 (Us$Mn)
    • Table 11.61 Watson Pharmaceuticals Drug Delivery Portfolio, 2008
    • Table 11.62 Zogenix Pharmaceuticals Drug Delivery Portfolio, 2008
      • Graphs
      • Graph 3.1 Estimated Drug Delivery Market By Main Geographic Regions
      • Graph 3.2 Global Sales Of Drug Delivery Systems By Key Segments, 2007
      • Graph 3.3 Forecast Global Sales Of Drug Delivery Market By Segment, Us$ Billion
      • Graph 3.4 Forecast 2007-2012 Growth Of Global Drug Delivery Market By Segment
      • Graph 4.1 Top 5 Products Utilizing Oral Delivery, Global Sales 2007 ($ Mn)
      • Graph 4.2 Leading Oral Drug Delivery Companies, Combined Key Product Values 2007 ($ Mn)
      • Graph 4.3 Key Therapeutic Areas Of Emphasis For Oral Drug Delivery, # Of Key Marketed Products, 2007
      • Graph 4.4 Top 5 Products Utilizing Inhalable Delivery, Global Sales 2007 ($ Mn)
      • Graph 4.5 Inhalable Drug Delivery Market Share, By Technology 2007
      • Graph 4.6 Top 5 Products Utilizing Injectable Delivery, Global Sales 2007 ($ Mn)
      • Graph 4.7 Leading Injectable Drug Delivery Companies, Combined Key Product Values 2007 ($ Mn)
      • Graph 4.8 Top 5 Products Utilizing Transmucosal Delivery, Global Sales 2007 ($ Mn)
      • Graph 4.9 Leading Developers Of Transmucosal-Based Therapeutics 2007 ($ Mn)
      • Graph 4.10 Leading Transdermal Drug Delivery Companies, By # Of Products On Market
      • Graph 4.11 Key Therapeutic Areas Of Emphasis For Transdermal Drug Delivery, # Of Key Marketed Products
      • Graph 5.1 Leading Companies Active In Oral Drug Delivery Development
      • Graph 5.2 Leading Indications For Oral Drug Delivery Products In Development
      • Graph 6.1 Leading Companies Active In Inhalable Drug Delivery Development
      • Graph 7.1 Leading Companies Active In Injectable Drug Delivery Development
      • Graph 8.1 Leading Companies Active In Injectable Drug Delivery Development
      • Graph 9.1 Leading Companies Active In Transdermal Drug Delivery Development
      • Graph 10.1 Leading Companies Active In Niche/Topical Drug Delivery Development
    • Figures
    • Figure 1.1 Optimal Time For Reformulation
    • Figure 1.2 Growth Prospects In The Drug Delivery Sector
    • Figure 2.1 Pulsatile Drug Release